Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Inv. presentation
Cert. of designation
Quarterly results
Acq. announced
|
|
HARROW HEALTH, INC. (IMMY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Quarterly results|
Docs:
|
"HARROW HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2022 December 31, 2021 ASSETS Cash and cash equivalents $ 46,438,000 $ 42,167,000 All other current assets 18,265,000 18,495,000 Total current assets 64,703,000 60,662,000 All other assets 33,359,000 37,667,000 TOTAL ASSETS $ 98,062,000 $ 98,329,000 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities $ 12,922,000 $ 9,722,000 Senior April 2026 Notes, net of discount 72,042,000 71,654,000 All other liabilities 7,704,000 6,022,000 TOTAL LIABILITIES 92,668,000 87,398,000 TOTAL STOCKHOLDERS’ EQUITY 5,394,000 10,931,000 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 98,062,000 $ 98,329,000 -MORE- HROW Announces Second Quarter 2022 Financial Results Page 4 August 9, 2022 HARROW HEALTH, INC. UNAUDITED CONDENSED CONSOLIDATED STAT...",
"Second Quarter Core Results" |
|
| 03/10/2022 |
8-K
| Quarterly results|
Docs:
|
"Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results Sixth Consecutive Quarter of Record Revenues Highlights for Fourth Quarter 2021:",
"Harrow Health, Inc. Letter to Stockholders March 10, 2022 To the Stockholders of Harrow Health, Inc.: As a result of the remarkable collective effort of the Harrow family of employees and the patronage of our valued customers, it is my privilege to report that the fourth quarter of 2021 was our sixth consecutive quarter of record performance in many key financial and operational metrics, providing a solid conclusion to 2021 and a springboard for 2022 and beyond. Throughout 2021, our team worked diligently to advance our goal of making Harrow a leading U.S. eyecare company. We bolstered our balance sheet, completed several dynamic transactions, successfully filed our first New Drug Application with the U.S. Food and Drug Administration , continued to work on new potentially accretive deals,..." |
|
| 05/11/2021 |
8-K
| Quarterly results |
| 03/08/2021 |
8-K
| Quarterly results |
| 11/17/2020 |
8-K
| Quarterly results|
Docs:
|
"Harrow Health Publishes Third Quarter 2020 Letter to Stockholders",
"Harrow Health, Inc. Letter to Stockholders November 9, 2020 To the Stockholders of Harrow Health, Inc.: The third quarter of 2020 was the best financial quarter in the history of the Company. Our team delivered on revenues, gross margins, and nearly every other internal metric that we chart. Revenues in July were better than June; and each subsequent month continued to improve. We were also pleased that while we achieved Q3 record revenues, we also hit an Adjusted EBITDA record, an important correlative trend we expect to continue as revenues grow. Finally, from a financial perspective, we expect that an increasing percentage of each incremental dollar of additive revenue will improve our Adjusted EBITDA figure. As we move into the fourth quarter and set our sights on 2021, we are hopeful ..." |
|
| 11/09/2020 |
8-K
| Quarterly results|
Docs:
|
"Harrow Health Publishes Third Quarter 2020 Letter to Stockholders",
"Harrow Health, Inc. Letter to Stockholders November 9, 2020 To the Stockholders of Harrow Health, Inc.: The third quarter of 2020 was the best financial quarter in the history of the Company. Our team delivered on revenues, gross margins, and nearly every other internal metric that we chart. Revenues in July were better than June; and each subsequent month continued to improve. We were also pleased that while we achieved Q3 record revenues, we also hit an Adjusted EBITDA record, an important correlative trend we expect to continue as revenues grow. Finally, from a financial perspective, we expect that an increasing percentage of each incremental dollar of additive revenue will improve our Adjusted EBITDA figure. As we move into the fourth quarter and set our sights on 2021, we are hopeful ..." |
|
| 08/10/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 03/13/2020 |
8-K
| Quarterly results |
| 11/13/2019 |
8-K
| Quarterly results |
| 05/09/2019 |
8-K
| Quarterly results |
| 03/12/2019 |
8-K
| Quarterly results |
| 11/13/2018 |
8-K
| Quarterly results |
| 08/06/2018 |
8-K
| Quarterly results |
| 05/15/2018 |
8-K
| Quarterly results |
| 03/08/2018 |
8-K
| Quarterly results |
| 08/10/2017 |
8-K
| Quarterly results |
| 05/10/2017 |
8-K
| Form 8-K - Current report |
| 03/21/2017 |
8-K
| Form 8-K - Current report |
| 11/15/2016 |
8-K
| Form 8-K - Current report |
| 05/12/2016 |
8-K
| Form 8-K - Current report |
| 03/23/2016 |
8-K
| Form 8-K - Current report |
| 11/12/2015 |
8-K
| Quarterly results |
| 08/12/2015 |
8-K
| Quarterly results |
| 05/13/2015 |
8-K
| Quarterly results |
| 03/12/2015 |
8-K
| Quarterly results |
| 11/12/2014 |
8-K
| Quarterly results |
| 08/13/2014 |
8-K
| Quarterly results |
| 11/08/2010 |
8-K
| Form 8-K - Current report |
| 05/13/2010 |
8-K
| Form 8-K - Current report |
|
|